Patents by Inventor Timothy John Norman

Timothy John Norman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12018021
    Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: June 25, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Pfrafulkumar Tulshibhai Chovatia, Rickki Lee Connelly, Richard Jeremy Franklin, Gregory William Haslett, Alistair James Henry, James Madden, Judi Charlotte Neuss, Timothy John Norman, Oliver Philps, William Ross Pitt, Konstantinos Rampalakos, Matthew Duncan Selby, Selvaratnam Suganthan, Giancarlo Trani, Zhaoning Zhu
  • Publication number: 20240140951
    Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
    Type: Application
    Filed: December 6, 2021
    Publication date: May 2, 2024
    Inventors: Gareth Neil Brace, Shuyu Chu, Anne Marie Foley, James Andrew Johnson, Timothy John Norman, Joanna Rachel Quincey, James Thomas Reuberson, Robert Straker, Robert James Townsend
  • Publication number: 20240092773
    Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the Fc?RI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: March 21, 2024
    Inventors: Timothy John NORMAN, Zhaoning ZHU, Selvaratnam SUGANTHAN, Konstantinos RAMPALAKO, James MADDEN, Jag Paul HEER, Richard Jeremy FRANKLIN, Rickki Lee CONNELLY, Thierry DEMAUDE, Gregory William HASLETT, Benedicte LALLEMAND, Nathaniel Julius Thomas MONCK, Julian Hugh ROWLEY, Giancarlo TRANI
  • Publication number: 20230303517
    Abstract: The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: September 28, 2023
    Inventors: Timothy John NORMAN, Douglas BYRNE, Julian Hugh ROWLEY, Giancarlo TRANI, Konstantinos RAMPALAKOS, Nathaniel Julius Thomas MONCK, Benedicte LALLEMAND, Gregory William HASLETT, Rickki Lee CONNELLY, Jag Paul HEER, James MADDEN, Oliver PHILPS, Selvaratnam SUGANTHAN, Zeshan YOUSUF, Richard John MEARS
  • Publication number: 20230192646
    Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: June 22, 2023
    Inventors: Timothy John NORMAN, Jag Paul HEER, Oliver PHILPS, William Ross PITT, James MADDEN, Zeshan YOUSUF
  • Publication number: 20230194541
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. Anew assay for identifying compounds with this mechanism of action is also disclosed.
    Type: Application
    Filed: August 30, 2022
    Publication date: June 22, 2023
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW
  • Patent number: 11674967
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 13, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow, Tracy Lynn Arakaki, Alex Buntin Burgin, William Ross Pitt, Mark Daniel Calmiano, David Andreas Schubert, Daniel John Lightwood, Rebecca Jayne Munro
  • Publication number: 20230050670
    Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamide derivatives of formula (1), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 16, 2023
    Inventors: Timothy John NORMAN, Selvaratnam SUGANTHAN, Jag Paul HEER, Zeshan YOUSUF
  • Publication number: 20230051300
    Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.
    Type: Application
    Filed: December 22, 2020
    Publication date: February 16, 2023
    Inventors: Timothy John NORMAN, Oliver PHILPS, Gregory William HASLETT, Jag Paul HEER, Giancarlo TRANI
  • Publication number: 20220332709
    Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.
    Type: Application
    Filed: June 20, 2019
    Publication date: October 20, 2022
    Inventors: Pfrafulkumar Tulshibhai Chovatia, Rickki Lee Connelly, Richard Jeremy Franklin, Gregory William Haslett, Alistair James Henry, James Madden, Judi Charlotte Neuss, Timothy John Norman, Oliver Philps, William Ross Pitt, Konstantinos Rampalakos, Matthew Duncan Selby, Suganthan Selvaratnam, Giancarlo Trani, Zhaoning Zhu
  • Patent number: 11448655
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: September 20, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow
  • Publication number: 20210140972
    Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.
    Type: Application
    Filed: October 16, 2020
    Publication date: May 13, 2021
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, David James MCMILLAN, Graham John WARRELLOW, Daniel Christopher BROOKINGS, Rikki Peter ALEXANDER
  • Publication number: 20210088530
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Application
    Filed: September 4, 2020
    Publication date: March 25, 2021
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW, Tracy Lynn ARAKAKI, Alex Buntin BURGIN, William Ross PITT, Mark Daniel CALMIANO, David Andreas SCHUBERT, Daniel John LIGHTWOOD, Rebecca Jayne MUNRO
  • Patent number: 10883996
    Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: January 5, 2021
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, David James McMillan, Graham John Warrellow, Daniel Christopher Brookings, Rikki Peter Alexander
  • Publication number: 20200400678
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.
    Type: Application
    Filed: May 26, 2020
    Publication date: December 24, 2020
    Inventors: James Philip O'CONNELL, John Robert PORTER, Alastair LAWSON, Boris KROEPLIEN, Stephen Edward RAPECKI, Timothy John NORMAN, Graham John WARRELLOW
  • Patent number: 10842884
    Abstract: Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C6 to C24 alkylene or alkenylene group, which is optionally interrupted by one or more —NR9—, —O— or —S— linkages, R2 is —YC(R4)(R5)CO2R6; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: November 24, 2020
    Assignee: UCB Biopharma SRL
    Inventors: Terence Seward Baker, Michael Anthony William Eaton, Timothy John Norman, James Petrie Turner
  • Patent number: 10775385
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: September 15, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow, Tracy Lynn Arakaki, Alex Buntin Burgin, William Ross Pitt, Mark Daniel Calmiano, David Andreas Schubert, Daniel John Lightwood, Rebecca Jayne Wootton
  • Patent number: 10705094
    Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: July 7, 2020
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow
  • Publication number: 20190298859
    Abstract: Compounds of formula (I), wherein Ar is an aryl group optionally further substituted with one or more groups R3; A is a lipophilic, hydrophobic moiety; R1 is a phosphodiester, phosphotriester, thioether or amide group; X is an unsubstituted or substituted C6 to C24 alkylene or alkenylene group, which is optionally interrupted by one or more —NR9—, —O— or —S— linkages, R2 is —YC(R4)(R5)CO2R6; and pharmaceutically acceptable salts or solvates thereof are useful as endosomolytic agents particularly for the delivery of nucleic acids useful in gene therapy.
    Type: Application
    Filed: September 27, 2017
    Publication date: October 3, 2019
    Inventors: Terence Seward Baker, Michael Anthony William Eaton, Timothy John Norman, James Petrie Turner
  • Patent number: 10287299
    Abstract: A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: May 14, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu